Elicera Therapeutics AB (OSTO:ELIC) COGS-to-Revenue : 0.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB COGS-to-Revenue?

Elicera Therapeutics AB's Cost of Goods Sold for the three months ended in Jun. 2024 was kr0.00 Mil. Its Revenue for the three months ended in Jun. 2024 was kr0.00 Mil.

Elicera Therapeutics AB's COGS to Revenue for the three months ended in Jun. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Elicera Therapeutics AB's Gross Margin % for the three months ended in Jun. 2024 was N/A%.

Elicera Therapeutics AB COGS-to-Revenue Historical Data

The historical data trend for Elicera Therapeutics AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB COGS-to-Revenue Chart

Elicera Therapeutics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Elicera Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
COGS-to-Revenue	Get a 7-Day Free Trial														-	-	-	-	-

Elicera Therapeutics AB COGS-to-Revenue Calculation

Elicera Therapeutics AB's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Elicera Therapeutics AB's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Elicera Therapeutics AB (OSTO:ELIC) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Elicera Therapeutics AB's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Elicera Therapeutics AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB Headlines

No Headlines